Topic:

M&A

Latest Headlines

Latest Headlines

Renewed Stryker takeover rumor sends Smith & Nephew stock up

Ever since Zimmer agreed to purchase Biomet for $13.4 billion in April 2014, the wait for takeover of Smith & Nephew has been on, with Stryker being the most likely acquirer. Rumors of an impending deal were just renewed by a StreetInsider report that Stryker has put an $18 billion offer for Smith & Nephew on the table, sending its stock up as much as 6%.

Shire prepared to walk on Baxalta talks if deal doesn't come soon: WSJ

Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to the deal, who told the newspaper the Dublin drugmaker expects to ink a pact or walk away "reasonably soon."

On the rebound, AMRI trades $52M for a testing firm

AMRI, a contract drugmaker returning to profitability after years of restructuring, bought a New Jersey testing firm for $54 million, expanding its stable of services.

AstraZeneca bets $7B on Acerta's potential blockbuster cancer treatment

AstraZeneca is buying big into the promise of Acerta Pharma's in-development blood cancer therapy, signing on to buy a majority stake in the company in a deal that could be worth up to $7 billion.

PPD reportedly on the block for $8B

The private equity owners of CRO giant PPD are looking to either sell the company or take it public, according to Reuters, moves that would follow a trend in the pharma contracting industry.

Sanofi-Boehringer talks may signal more swaps ahead for 'merger mania' in 2016

Is the swap destined to be pharma's next M&A trend? When dealmakers tot up the advantages of Sanofi and Boehringer Ingelheim's asset-trade talks--and add them to the big GlaxoSmithKline-Novartis swap-out earlier this year--they might follow up with barter arrangements of their own, M&A experts say.

Sanofi's poised for No. 1 in consumer health, but Bayer plans to fight back with M&A

The consumer health space is consolidating rapidly--and Bayer knows it. It also knows its whopper $14.2 billion deal for Merck & Co.'s consumer business last year isn't going to be enough to keep it on the OTC leaderboard.

Capsugel gets more manufacturing expertise with two-company deal

Capsulemaker and drug formulation specialist Capsugel is adding to its manufacturing and broadening its dosing form capabilities with a deal to buy not one but two different companies and pick up 210 employees in the process.

Sanofi plots $12.5B Merial tradeoff with Boehringer, gaining consumer unit in the bargain

Novartis and GlaxoSmithKline may have started a trend with their big sale-and-swap announced last year. Now, it's Sanofi and Boehringer Ingelheim working on a trade, with the French drugmaker's animal health business moving to Boehringer in exchange for the latter's consumer healthcare unit.

Icahn: Change the international tax code, and Pfizer will drop its 'travesty' of a merger

The tax benefits of buying Allergan are Pfizer's No. 1 reason for doing the $160 billion deal. In fact, some analysts see the $2 billion in potential tax savings as the merger's only substantial advantage.